Elderly have trouble with Relenza Diskhaler, says BMJ study

8 March 2001

Most elderly people cannot use the inhaler device that deliversGlaxoSmithKline's influenza drug Relenza (zanamivir), even after tuition, according to a report in the British Medical Journal (March 10). The researchers suggest that improvements should be made to the Diskhaler device used to deliver the drug, noting that zanamivir treatment for elderly people with flu is unlikely to be effective unless delivery is improved. Particular attention should be paid to the loading and priming of the device, the researchers conclude.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight